Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
29.73
+0.18 (0.61%)
At close: Mar 13, 2025, 4:00 PM
30.10
+0.37 (1.24%)
After-hours: Mar 13, 2025, 7:59 PM EST
Viking Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 49.28 | 37.02 | 16.12 | 10.7 | 10.73 | |
| Research & Development | 101.64 | 63.81 | 54.23 | 44.98 | 31.93 | |
| Operating Expenses | 150.92 | 100.83 | 70.36 | 55.68 | 42.66 | |
| Operating Income | -150.92 | -100.83 | -70.36 | -55.68 | -42.66 | |
| Interest Expense | -0.09 | -0.09 | -0.06 | -0.02 | -0.11 | |
| Interest & Investment Income | 40.94 | 15.02 | 1.59 | 0.7 | 3.23 | |
| Currency Exchange Gain (Loss) | - | - | - | 0.01 | - | |
| EBT Excluding Unusual Items | -110.08 | -85.9 | -68.83 | -54.99 | -39.54 | |
| Gain (Loss) on Sale of Investments | 0.11 | - | -0.04 | - | 0.04 | |
| Pretax Income | -109.96 | -85.9 | -68.87 | -54.99 | -39.5 | |
| Net Income | -109.96 | -85.9 | -68.87 | -54.99 | -39.5 | |
| Net Income to Common | -109.96 | -85.9 | -68.87 | -54.99 | -39.5 | |
| Shares Outstanding (Basic) | 109 | 94 | 77 | 77 | 73 | |
| Shares Outstanding (Diluted) | 109 | 94 | 77 | 77 | 73 | |
| Shares Change (YoY) | 15.57% | 22.79% | -0.47% | 6.34% | 0.89% | |
| EPS (Basic) | -1.01 | -0.91 | -0.90 | -0.71 | -0.54 | |
| EPS (Diluted) | -1.01 | -0.91 | -0.90 | -0.71 | -0.54 | |
| Free Cash Flow | -87.79 | -73.38 | -48.4 | -47.59 | -21.78 | |
| Free Cash Flow Per Share | -0.81 | -0.78 | -0.63 | -0.62 | -0.30 | |
| EBIT | -150.92 | -100.83 | -70.36 | -55.68 | -42.66 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.